Royal Bank of Canada’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $0 | Sell |
70
-836
| -92% | -$5.96K | ﹤0.01% | 7606 |
|
|
2025
Q4 | $7K | Sell |
906
-35,316
| -97% | -$286K | ﹤0.01% | 6601 |
|
|
2025
Q3 | $370K | Buy |
36,222
+17,922
| +98% | +$201K | ﹤0.01% | 4702 |
|
|
2025
Q2 | $190K | Buy |
18,300
+15,915
| +667% | +$169K | ﹤0.01% | 5208 |
|
|
2025
Q1 | $31K | Sell |
2,385
-3,077
| -56% | -$55K | ﹤0.01% | 5764 |
|
|
2024
Q4 | $98K | Buy |
5,462
+2,524
| +86% | +$51.1K | ﹤0.01% | 5350 |
|
|
2024
Q3 | $47K | Buy |
2,938
+125
| +4% | +$1.95K | ﹤0.01% | 5729 |
|
|
2024
Q2 | $76K | Buy |
2,813
+595
| +27% | +$14.2K | ﹤0.01% | 5434 |
|
|
2024
Q1 | $44K | Sell |
2,218
-1,622
| -42% | -$34.4K | ﹤0.01% | 5590 |
|
|
2023
Q4 | $79K | Sell |
3,840
-434
| -10% | -$13K | ﹤0.01% | 5756 |
|
|
2023
Q3 | $136K | Buy |
4,274
+1,391
| +48% | +$46.5K | ﹤0.01% | 5138 |
|
|
2023
Q2 | $97K | Buy |
2,883
+355
| +14% | +$12.7K | ﹤0.01% | 5364 |
|
|
2023
Q1 | $105K | Buy |
2,528
+13
| +0.5% | +$611 | ﹤0.01% | 5145 |
|
|
2022
Q4 | $86K | Sell |
2,515
-10
| -0.4% | -$425 | ﹤0.01% | 5565 |
|
|
2022
Q3 | $124K | Buy |
2,525
+25
| +1% | +$1.37K | ﹤0.01% | 5170 |
|
|
2022
Q2 | $98K | Sell |
2,500
-205
| -8% | -$6.08K | ﹤0.01% | 5344 |
|
|
2022
Q1 | $100K | Sell |
2,705
-384
| -12% | -$24K | ﹤0.01% | 5647 |
|
|
2021
Q4 | $303K | Buy |
3,089
+295
| +11% | +$31.7K | ﹤0.01% | 4927 |
|
|
2021
Q3 | $349K | Buy |
2,794
+63
| +2% | +$7.61K | ﹤0.01% | 4656 |
|
|
2021
Q2 | $343K | Buy |
2,731
+66
| +2% | +$7.86K | ﹤0.01% | 4607 |
|
|
2021
Q1 | $361K | Buy |
2,665
+66
| +3% | +$8.19K | ﹤0.01% | 4452 |
|
|
2020
Q4 | $236K | Buy |
2,599
+2,581
| +14,339% | +$224K | ﹤0.01% | 4747 |
|
|
2020
Q3 | $1K | Buy |
+18
| New | +$1.38K | ﹤0.01% | 6471 |
|
|
2018
Q4 | – | Sell |
-11
| Closed | -$5K | – | 7053 |
|
|
2018
Q3 | $5K | Buy |
11
+1
| +10% | +$402 | ﹤0.01% | 6274 |
|
|
2018
Q2 | $4K | Buy |
+10
| New | +$3.55K | ﹤0.01% | 6108 |
|
|
2018
Q1 | – | Sell |
-1
| Closed | – | – | 6722 |
|
|
2017
Q4 | $0 | Sell |
1
-41
| -98% | -$17.9K | ﹤0.01% | 6823 |
|
|
2017
Q3 | $23K | Buy |
+42
| New | +$22.3K | ﹤0.01% | 5880 |
|
|
2017
Q2 | – | Sell |
-11
| Closed | -$5K | – | 6732 |
|
|
2017
Q1 | $5K | Buy |
11
+1
| +10% | +$421 | ﹤0.01% | 6221 |
|
|
2016
Q4 | $5K | Buy |
10
+7
| +233% | +$4.09K | ﹤0.01% | 6302 |
|
|
2016
Q3 | $1K | Buy |
+3
| New | +$1.17K | ﹤0.01% | 6302 |
|
Other funds holding RNAC
VCM
6CM
EAM
Royal Bank of Canada's RNAC Position: Q1 2026 in Review
Royal Bank of Canada reduced its Cartesian Therapeutics (RNAC) stake by 92% in Q1 2026, selling an estimated $5.96K and leaving 70 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7606.
Royal Bank of Canada first reported a position in RNAC in Q3 2016 and has held it in 30 quarters since. The position peaked at $370K in Q3 2025. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.
- Royal Bank of Canada held 70 shares of Cartesian Therapeutics worth $0 as of Q1 2026.
- Royal Bank of Canada sold 836 Cartesian Therapeutics shares in Q1 2026, an estimated $5.96K.
- Cartesian Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7606 holding.
- Royal Bank of Canada first reported a position in Cartesian Therapeutics in Q3 2016 and has held it in 30 quarters since.
- Royal Bank of Canada's Cartesian Therapeutics position peaked at $370K in Q3 2025.
- 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.